SOURCE: Entest BioMedical, Inc.

Entest BioMedical, Inc.

March 23, 2010 16:00 ET

Entest BioMedical Files Patent Application on Chemokine Technology to Increase Efficacy of Tissue-Specific Stem Cell Homing in COPD Treatment

Entest CEO and Lead Inventor to Discuss Chemokine Technology on Webcast Wednesday, March 24, at 11:00 am PST - www.entestbioblog.com/live

SAN DIEGO, CA--(Marketwire - March 23, 2010) -  Entest BioMedical Inc. (OTCBB: ENTB) announced today the filing of a patent application covering the use of stem cell attracting molecules called chemokines in the treatment of Chronic Obstructive Pulmonary Disease (COPD) as well as other conditions that may benefit from enhanced stem cell homing. 

Chemokines are naturally produced by the body in times of tissue injury and are believed to be an essential part of the healing process. Entest's intellectual property utilizes these molecules to attract stem cells to damaged tissue in order to augment efficacy of both existing and newly developed cell therapies.

"Clinical trials of stem cells have demonstrated safety and signs of efficacy in heart failure, liver failure, and peripheral artery disease. Unfortunately there is still much room for improvement in patient outcomes," stated Dr. Steven Josephs, lead inventor of the patent application. "The current invention offers a means of making stem cell therapy work better by increasing the number of stem cells in the tissue where they are needed." 

The FDA has previously approved a drug which functions by alteration of stem cell homing. Mozobil, a drug developed by Genzyme Corporation, is used to induce stem cells to leave a specific anatomical location (bone marrow). The methods covered by the Entest patent application function in an opposite manner by utilizing specific molecules to attract stem cells.

"Today's patent filing represents Entest's global strategy of addressing COPD through a multi-disciplinary manner," said David Koos, Chairman and CEO of Entest. "Since some of these technologies may be useful in augmentation of stem cell therapy for other indications, we are always looking for partnerships for development in our non-core areas."

Entest's Chairman & CEO David Koos, along with lead inventor Dr. Steven Josephs will host a webcast discussion of this new technology on March 24, 2010 at 11:00 am PST. Interested parties can logon to the webcast at www.entestbioblog.com/live.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576™ is a proprietary laser device currently under development by Entest. The Company has filed 4 patent applications relating to the treatment of COPD. Entest Biomedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at http://www.translational-medicine.com/content/pdf/1479-5876-7-106.pdf.

Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information